{"id":"trinessa","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00360425","NCT00130117","NCT05307614","NCT02589782","NCT05293171","NCT03280004","NCT01091493","NCT00936871","NCT00709189","NCT00543062","NCT01359618","NCT02717871","NCT02322619","NCT03363295","NCT05061472","NCT02164812","NCT02496572","NCT04310930","NCT04045769","NCT05398679","NCT02098486","NCT07209761","NCT03580473","NCT03657446","NCT02911870","NCT01265641","NCT02062203","NCT06411860","NCT02792517","NCT02785770","NCT06917495","NCT00455806","NCT01811225","NCT01643889","NCT02917200","NCT01999114","NCT00809289","NCT00713336","NCT01537887","NCT01762839","NCT00042289","NCT00447629","NCT00728507","NCT00434395","NCT01298336","NCT02559310","NCT06427629","NCT02816905","NCT06162286","NCT01577342"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Trinessa","companyId":"corewell-health-east","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Corewell Health East","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Trinessa","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00360425","phase":"Phase 1","title":"A Phase 1 Active- and Placebo-Controlled Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women","status":"COMPLETED","sponsor":"AMAG Pharmaceuticals, Inc.","isPivotal":false,"enrollment":174,"indication":"Anemia","completionDate":"2006-08"},{"nctId":"NCT00130117","phase":"Phase 2","title":"Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","isPivotal":false,"enrollment":20,"indication":"Amenorrhea","completionDate":"2016-12"},{"nctId":"NCT05307614","phase":"Phase 1","title":"A Single Center, Open Label, Randomized, Single-dose, 2 Way Cross-over Study to Explore the Relative Bioavailability of Moksi 400mg (Moxifloxacin) Tablet and Avelox 400mg (Moxifloxacin) Tablet Under F","status":"COMPLETED","sponsor":"Abbott","isPivotal":false,"enrollment":38,"indication":"Bioequivalence","completionDate":"2019-04-27"},{"nctId":"NCT02589782","phase":"Phase 2","title":"A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multid","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","isPivotal":true,"enrollment":552,"indication":"Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis","completionDate":"2022-08-05"},{"nctId":"NCT05293171","phase":"Phase 1","title":"A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Positive-Controlled, Four-Way Crossover Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","isPivotal":false,"enrollment":38,"indication":"Healthy Subjects","completionDate":"2022-08-15"},{"nctId":"NCT03280004","phase":"N/A","title":"Reason Evaluation of Initial Treatment Failure in Patients With Community Acquired Pneumonia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","isPivotal":false,"enrollment":314,"indication":"Community-acquired Pneumonia","completionDate":"2019-11-30"},{"nctId":"NCT01091493","phase":"Phase 4","title":"Utility of Antibiotic Treatment in Acute Non-purulent Exacerbations of COPD: a Double Blinded, Randomized, Placebo-controlled Trial of Security and Efficacy","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","isPivotal":false,"enrollment":73,"indication":"Chronic Obstructive Pulmonary Disease","completionDate":"2018-07-05"},{"nctId":"NCT00936871","phase":"Phase 1","title":"A Phase 1, Randomized, Single Dose, Placebo And Active Controlled, 3-Way Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":66,"indication":"Healthy Volunteers","completionDate":"2010-03"},{"nctId":"NCT00709189","phase":"Phase 1","title":"A Pivotal Bioequivalence Study of 250 Mcg NGM/35 Mcg EE With or Without Folic Acid in Healthy Female Subjects.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":false,"enrollment":53,"indication":"Female Contraception, Contraception","completionDate":"2005-08"},{"nctId":"NCT00543062","phase":"Phase 1","title":"Thorough QT/QTc Study of Staccato® Prochlorperazine for Inhalation in Healthy Volunteers","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","isPivotal":false,"enrollment":48,"indication":"Cardiotoxicity","completionDate":"2007-12"},{"nctId":"NCT01359618","phase":"Phase 1","title":"A Single-centre, Randomised, Double-blind, Placebo Controlled Phase I Study in Two Parts: Part A to Assess a Safe and Tolerable Supratherapeutic Dose of TC-5214 After Single Ascending Oral Doses in He","status":"TERMINATED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":16,"indication":"Healthy Male","completionDate":"2012-04"},{"nctId":"NCT02717871","phase":"Phase 3","title":"Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","isPivotal":true,"enrollment":35,"indication":"Keratitis; Infectious Disease (Manifestation)","completionDate":"2020-10"},{"nctId":"NCT02322619","phase":"Phase 1","title":"An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Moxifloxacin Tablets, 400 mg of Dr. Reddy's Laboratories Limited, Com","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":26,"indication":"Healthy","completionDate":"2012-12"},{"nctId":"NCT03363295","phase":"Phase 4","title":"Evaluation and Comparison of Macular and Choroidal Thickness After Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis","status":"COMPLETED","sponsor":"Universidade Federal de Pernambuco","isPivotal":false,"enrollment":120,"indication":"Endophthalmitis, Macula Edema","completionDate":"2019-12-30"},{"nctId":"NCT05061472","phase":"N/A","title":"The Influence of Combined Oral Contraceptives on Weight, Body Composition, Eating Behaviors, and Appetite in Pre-menopausal Women With Overweight or Obesity","status":"COMPLETED","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":20,"indication":"Contraceptive Usage, Overweight or Obesity","completionDate":"2023-08-23"},{"nctId":"NCT02164812","phase":"Phase 1","title":"A Study to Determine the Concentration-Electrocardiographic Effects of Efavirenz in Healthy Subjects Enriched for CYP2B6 Polymorphisms","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":58,"indication":"HIV/AIDS","completionDate":"2015-08"},{"nctId":"NCT02496572","phase":"N/A","title":"Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","isPivotal":false,"enrollment":110,"indication":"Multidrug Resistant Tuberculosis","completionDate":"2016-04"},{"nctId":"NCT04310930","phase":"Phase 2","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT)","status":"RECRUITING","sponsor":"The University of Queensland","isPivotal":true,"enrollment":300,"indication":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","completionDate":"2030-06-30"},{"nctId":"NCT04045769","phase":"Phase 1","title":"A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","isPivotal":false,"enrollment":52,"indication":"Healthy","completionDate":"2019-12-02"},{"nctId":"NCT05398679","phase":"Phase 4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","isPivotal":false,"enrollment":360,"indication":"Endocarditis Infective","completionDate":"2027-12-30"},{"nctId":"NCT02098486","phase":"Phase 2","title":"Antibiotic Prophylaxis for ERCP: a Comparison of Intravenous Ceftriaxone With Intravenous Moxifloxacin in the Prophylaxis of Cholangitis","status":"COMPLETED","sponsor":"Kangbuk Samsung Hospital","isPivotal":false,"enrollment":86,"indication":"Cholangitis","completionDate":"2015-09"},{"nctId":"NCT07209761","phase":"Phase 3","title":"A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of 4-month and 6-month Quabodepistat-containing Regimens for Rifampicin-resistant/Multidrug-resi","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":532,"indication":"Pulmonary Tuberculosis","completionDate":"2028-09-29"},{"nctId":"NCT03580473","phase":"Phase 2","title":"Phase II, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification","status":"COMPLETED","sponsor":"EMS","isPivotal":false,"enrollment":118,"indication":"Ocular Inflammation, Cataract","completionDate":"2022-03-01"},{"nctId":"NCT03657446","phase":"Phase 1","title":"Randomized, Double-blind (for Clazosentan), Placebo- and Moxifloxacincontrolled, 3-way Cross-over Phase 1 Study to Assess the Effect of Two Intravenous Doses of Clazosentan on the QTc Interval Duratio","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","isPivotal":false,"enrollment":36,"indication":"Healthy Subjects","completionDate":"2018-10-26"},{"nctId":"NCT02911870","phase":"Phase 1","title":"A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","isPivotal":false,"enrollment":84,"indication":"Healthy","completionDate":"2017-05-11"},{"nctId":"NCT01265641","phase":"Phase 1","title":"A Single-centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four-period Crossover Study in Healthy Male Volunteers, to Assess the Effect on QT/QTc Interval of Single Oral Doses of AZD","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":44,"indication":"Asthma","completionDate":"2011-04"},{"nctId":"NCT02062203","phase":"Phase 1","title":"A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Vo","status":"COMPLETED","sponsor":"Akebia Therapeutics","isPivotal":false,"enrollment":50,"indication":"Healthy Volunteers","completionDate":"2014-04"},{"nctId":"NCT06411860","phase":"Phase 1","title":"A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":32,"indication":"Basic Science","completionDate":"2024-12-11"},{"nctId":"NCT02792517","phase":"Phase 1","title":"A Multi-Center, Open-label, Pharmacokinetic Drug Interaction Study of AMG 334 and a Combined Oral Contraceptive in Healthy Female Subjects","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":41,"indication":"Headache, Migraine","completionDate":"2016-09-09"},{"nctId":"NCT02785770","phase":"Phase 1","title":"A Phase 1, Single-dose, Randomized, 4-treatment, 4-period Crossover, Placebo- And Positive-controlled, Double-blind (Open-label For Positive Control), Sponsor-open Study To Determine The Effect Of PF-","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":44,"indication":"Healthy","completionDate":"2016-10-20"},{"nctId":"NCT06917495","phase":"Phase 2","title":"Rifapentine- And Moxifloxacin-Containing Short-Course Regimens for Mild Spinal Tuberculosis: A Multicenter, Randomized, Non-inferiority Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","isPivotal":false,"enrollment":300,"indication":"Mild Spinal Tuberculosis","completionDate":"2029-12-31"},{"nctId":"NCT00455806","phase":"Phase 3","title":"Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infect","status":"UNKNOWN","sponsor":"Technische Universität Dresden","isPivotal":true,"enrollment":132,"indication":"Helicobacter Pylori Infection, Chronic Gastritis","completionDate":"2008-02"},{"nctId":"NCT01811225","phase":"Phase 2","title":"Smoking, Sex Hormones, and Pregnancy","status":"COMPLETED","sponsor":"University of Minnesota","isPivotal":false,"enrollment":95,"indication":"Nicotine Dependence, Contraception","completionDate":"2017-06"},{"nctId":"NCT01643889","phase":"Phase 1","title":"A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single- and Multiple-Dose, 4-Way Crossover Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Subjects","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":44,"indication":"Healthy","completionDate":"2012-11"},{"nctId":"NCT02917200","phase":"Phase 1","title":"Impact of Different DAV132 Dose Regimens (From 2 to 22.5 g/Day During 7 Days, Bid and Tid) on the Fecal Moxifloxacin Concentrations and the Intestinal Microbiota of Healthy Volunteers Treated With Mox","status":"COMPLETED","sponsor":"Da Volterra","isPivotal":false,"enrollment":150,"indication":"Healthy Subjects","completionDate":"2016-12-02"},{"nctId":"NCT01999114","phase":"Phase 1","title":"A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 mcg/Hour an","status":"COMPLETED","sponsor":"Purdue Pharma LP","isPivotal":false,"enrollment":328,"indication":"ECG Effects","completionDate":"2012-10"},{"nctId":"NCT00809289","phase":"Phase 1","title":"A Randomized, Multiple Dose, Placebo and Active Controlled 3-way Crossover Study to Investigate the Effects of Esreboxetine on QTc Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":40,"indication":"Fibromyalgia","completionDate":"2009-07"},{"nctId":"NCT00713336","phase":"Phase 1","title":"A Phase I, Double-blind, Double-dummy, Placebo-controlled, Randomised, Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval Com","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":40,"indication":"Healthy","completionDate":"2008-11"},{"nctId":"NCT01537887","phase":"Phase 1","title":"A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":72,"indication":"Healthy Volunteers","completionDate":"2012-06"},{"nctId":"NCT01762839","phase":"Phase 1","title":"A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","isPivotal":false,"enrollment":150,"indication":"Healthy","completionDate":"2013-02-11"},{"nctId":"NCT00042289","phase":"N/A","title":"Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":1578,"indication":"HIV Infections","completionDate":"2020-09-30"},{"nctId":"NCT00447629","phase":"Phase 1","title":"A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)- Controlled, 4-Period Crossover Study of the Effects of Single Oral Doses of PPM 204 on Cardiac Repolarization in Healthy Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":0,"indication":"Diabetes Mellitus","completionDate":"2007-03"},{"nctId":"NCT00728507","phase":"Phase 2","title":"A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":121,"indication":"Tuberculosis","completionDate":"2013-04"},{"nctId":"NCT00434395","phase":"Phase 1","title":"A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)-Controlled, 4-Period Crossover Study of the Effects of a Single Dose of MOA-728 Infused Intravenously on Cardiac Repolarization in He","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","isPivotal":false,"enrollment":0,"indication":"Healthy","completionDate":"2007-10"},{"nctId":"NCT01298336","phase":"Phase 3","title":"Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","isPivotal":true,"enrollment":92,"indication":"Atypical; Mycobacterium, Pulmonary, Tuberculous","completionDate":"2019-03"},{"nctId":"NCT02559310","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Ac","status":"COMPLETED","sponsor":"Nabriva Therapeutics AG","isPivotal":true,"enrollment":551,"indication":"Community Acquired Pneumonia","completionDate":"2017-05"},{"nctId":"NCT06427629","phase":"NA","title":"Investigator-initiated Exploratory Clinical Trial to Observe Conjunctival Goblet Cell Density Using an Anterior Segment Imaging Device in Patients With Ocular Surface Disease (ODS) and Patients Schedu","status":"RECRUITING","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":148,"indication":"Ocular Surface Disease","completionDate":"2026-06"},{"nctId":"NCT02816905","phase":"Phase 4","title":"Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery (Topical Rimexolone Versus Topical Dexamethasone and Topical Fluorometholone)","status":"COMPLETED","sponsor":"Cairo University","isPivotal":false,"enrollment":40,"indication":"Intraocular Pressure","completionDate":"2016-06"},{"nctId":"NCT06162286","phase":"Phase 3","title":"A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-acquired Bacterial Pne","status":"RECRUITING","sponsor":"Zai Lab (Hong Kong), Ltd.","isPivotal":true,"enrollment":100,"indication":"Community-acquired Bacterial Pneumonia","completionDate":"2025-11-30"},{"nctId":"NCT01577342","phase":"NA","title":"Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","isPivotal":false,"enrollment":56,"indication":"Age-Related Macular Degeneration","completionDate":"2011-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}